(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 October 2014 (02.10.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/159911 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2014/025441

(22) International Filing Date:
13 March 2014 (13.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/778,540 13 March 2013 (13.03.2013) US
61/808,381 4 April 2013 (04.04.2013) US

(71) Applicants: **SANOFI** [FR/FR]; 54, Rue La Boétie, F-75008 Paris (FR). **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607-5200 (US).

(72) Inventor; and
(71) Applicant : **TOMKINSON, Blake** [US/US]; c/o Sanofi-Aventis, 55 Corporate Drive, Bridgewater, NJ 08807 (US).

(72) Inventors: **AFTAB, Blake, T.**; c/o University of California, San Francisco, HDF Comprehensive Cancer Ctr, Box 0128, 1450 3rd Street, San Francisco, CA 94158 (US). **HANN, Byron, C.**; c/o University of California, San Francisco, HDF Comprehensive Cancer Ctr, Box 0875, 2340 Sutter Street, San Francisco, CA 94143 (US). **MARTIN, Thomas, G.**; c/o University of California, San Francisco, Hematology/oncology, Box 0324, 400 Parnassus Ave, UC Clinics, San Francisco, CA 94143 (US).

(74) Agent: **SUNDBY, Suzannah, K.**; Smith, Gambrell & Russell, LLP, 1055 Thomas Jefferson Street, NW, #400, Washington, DC 20007 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) Title: COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB




Fig. 9B

(57) Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

WO 2014/159911 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*